Navigation Links
MedQuist Reports First Quarter 2008 Results
Date:5/12/2008

54

Accrued expenses 18,492 18,989

Accrued compensation 13,815 14,826

Customer accommodation and quantification 17,596 18,459

Deferred income tax liability - current 4,783 4,783

Deferred revenue 17,486 16,023

Total current liabilities 82,376 85,834

Deferred income taxes 15,862 15,151

Other non-current liabilities 2,055 2,143

Shareholders' equity:

Common stock - no par value; authorized 60,000

shares; 37,544 and 37,544 shares issued and

outstanding, respectively 236,504 236,412

Retained earnings 68,459 72,876

Accumulated other comprehensive income 5,252 5,356

Total shareholders' equity 310,215 314,644

Total liabilities and shareholders' equity $410,508 $417,772

MedQuist Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(In thousands)

Unaudited

Three months ended

March 31,

2008 2007

Operating activities:

Net loss $(4,417) $(1,886)

Adjustments to reconcile net loss to cash

provided by (used in) operating activities:

Depreciation and amortization 4,289 3,885

Equity in income of affiliated company (16) (260)<
'/>"/>

SOURCE MedQuist Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. QLT reports initial proof of concept data for punctal plug delivery technology
2. Neurobiological Technologies Reports Third Quarter Financial Results
3. Bionovo Reports First Quarter 2008 Financial Results
4. WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting
5. Cardium Reports on First Quarter 2008 Highlights and Financial Results
6. Novavax Reports First Quarter 2008 Financial Results
7. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
8. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
9. Pharmos Corporation Reports 2008 First Quarter Results
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... VIEW, Calif. , Feb. 26, 2015  23andMe, ... of Kate Black as Privacy Officer and ... federal, and state privacy laws as well as health ... regulatory team, she will be responsible for reviewing, updating ... customers in the U.S. and abroad. She joined the ...
(Date:2/26/2015)... Fla. , Feb. 26, 2015 DuPont ... growth priorities driven by key research advancements and product ... at today,s Bank of America Merrill Lynch 2015 Global ... the challenge of building grain supplies the last two ... continue at the pace of the last decade, when ...
(Date:2/26/2015)... CLEVELAND , Feb. 26, 2015 BioEnterprise ... biomedical companies have attracted more than $2 billion in ... from local and national investors, strategic sources, state – ... Over half of the $2 billion has been raised ... announcement comes on the heels of the BioEnterprise ...
(Date:2/26/2015)... 2015 According to a new market ... For Transgenic Crops (Corn, Soybean, Cotton and Others), Synthetic ... Share, Growth, Trends and Forecast, 2013 – 2019,”the global ... in 2012 and is expected to reach USD 28,694.1 ... from 2013 to 2019. , Demand for food ...
Breaking Biology Technology:23andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3
... 2010 , , , ... Women Biologists, Chemists, Physicists and,Mathematicians Recognized Across the Developing World , ... The Elsevier Foundation, TWAS and TWOWS announced today that they are,recognizing ... Latin America and the Caribbean for their research excellence. The,announcement was ...
... ORLANDO, Fla. , June 26, 2010 ... and Company (NYSE: LLY ) today announced results ... ® (exenatide) injection added to Lantus ® (insulin ... targets without weight gain or increasing their risk of hypoglycemia. ...
... June 25 Interleukin Genetics, Inc. (NYSE Amex: ... , it received notification from the Corporate Compliance Staff of ... to initiate proceedings to delist the Company,s common stock because ... Exchange,s Company Guide due to stockholders, equity of less than ...
Cached Biology Technology:Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 2Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 3Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 4Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 5Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 6Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 7Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R) 2Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R) 3Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R) 4Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R) 5Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R) 6Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R) 7Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R) 8Interleukin Genetics, Inc. Receives Delisting Notification from NYSE Amex 2
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/5/2015)... Carolina , 5. Februar 2015 /PRNewswire/ ... als spezialisiertes Logistikunternehmen und hat eine neue ... klinische Logistikfirma (Clinical Logistics Organization – CLO) ... neuen Kampagne lautet First , mit ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... smell the coffee and enjoy a cup of it ... get your juices flowing. It might keep you going for ... cyclist, University of Illinois kinesiology and community health professor Robert ... fuel up on caffeine prior to hitting the pavement on ...
... a genetic engineering breakthrough that could help everyone from bed-ridden ... Nobel Prize winner Mario R. Capecchihave created a "switch" that ... muscle stem cells to monitor muscle regeneration in a living ... switch, or drug, that allows people to grow new muscle ...
... CA--A Cancer Genomics Browser developed by researchers at the ... to visualize and analyze data from studies aimed at ... of the disease. The browser consists of ... find patterns in the huge amounts of clinical and ...
Cached Biology News:A little java makes it easier to jive, researcher says 2A little java makes it easier to jive, researcher says 3A little java makes it easier to jive, researcher says 4Stem cell breakthrough: Monitoring the on switch that turns stem cells into muscle 2Cancer Genomics Browser gives cancer researchers a powerful new tool 2Cancer Genomics Browser gives cancer researchers a powerful new tool 3Cancer Genomics Browser gives cancer researchers a powerful new tool 4
RABBIT ANTI RAT AQUAPORIN 5...
The Light Diagnostics Calicivirus Genotype 1&2 Typing OligoDetect assay is applicable for the qualitative detection of calicivirus RNA generated by an in-house validated in vitro nucleic acid amplifi...
Recombinant Rat CINC-2 beta, CF...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SGG (Sheep gamma globulin) lysine through amide bonds. This product is homologous to NP-BSA....
Biology Products: